Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 8Cytokine Release Syndrome 3Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neurilemmoma 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Carcinoma, Renal Cell 1Advanced Malignant Solid Neoplasm 1

Interventions

Zidovudine 2Valganciclovir 2tocilizumab 1tanespimycin 1siltuximab 1liposomal doxorubicin 1Vincristine 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Multi-centric Castleman's Disease × siltuximab × Clear all
NCT01024036 2018-03-21

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Janssen Research & Development, LLC

Phase 2 Completed
79 enrolled 20 charts

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡